MYC and hepatocellular carcinoma: For example, patients with MYC deregulation can be screen with a panel of SSOs against synthetic lethal targets of MYC, while patients with mutations in CTNNB1, a frequent genetic alteration in HCC, can be screened with a panel of SSOs targeting the β‐catenin pathway.90